Xeris Biopharma Holdings (NASDAQ: XERS) has been gaining attention in the biotech industry due to its innovative drug pipeline and strong growth potential. As investors
Xeris Biopharma Holdings, Inc. (XERS) is an innovative biotherapeutics company. The company is engaged in the development and marketing of treatments for patients with gastroenterological,
Xeris Biopharma Holdings Inc. (XERS) became bullish on the news of its Recorlev® receiving FDA approval for Cushing’s syndrome patients. Consequently, the stock was trading
Sonoma Pharmaceuticals Inc. (SNOA) stock plunged -7.53% to $8.1 in the pre-market trading after reporting partnership with Crown Laboratories to launch Microcyn® technology-based anti-itch over-the-counter
This weekend, the U.S. government is packaging millions of doses of the coronavirus vaccine from Pfizer and BioNTech for distribution to places around the country,
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.